Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Equity Income (2018 - 2022)

Historic Equity Income for Theravance Biopharma (TBPH) over the last 5 years, with Q2 2022 value amounting to $28.1 million.

  • Theravance Biopharma's Equity Income rose 2828.15% to $28.1 million in Q2 2022 from the same period last year, while for Jun 2022 it was $118.8 million, marking a year-over-year increase of 6489.76%. This contributed to the annual value of $104.0 million for FY2021, which is 5194.34% up from last year.
  • Latest data reveals that Theravance Biopharma reported Equity Income of $28.1 million as of Q2 2022, which was up 2828.15% from $25.1 million recorded in Q1 2022.
  • Theravance Biopharma's 5-year Equity Income high stood at $35.3 million for Q4 2021, and its period low was $686000.0 during Q1 2018.
  • Over the past 5 years, Theravance Biopharma's median Equity Income value was $13.5 million (recorded in 2020), while the average stood at $15.0 million.
  • Per our database at Business Quant, Theravance Biopharma's Equity Income skyrocketed by 80801.75% in 2019 and then skyrocketed by 254.9% in 2021.
  • Theravance Biopharma's Equity Income (Quarter) stood at $5.4 million in 2018, then surged by 119.47% to $11.9 million in 2019, then soared by 69.05% to $20.1 million in 2020, then surged by 75.31% to $35.3 million in 2021, then decreased by 20.33% to $28.1 million in 2022.
  • Its Equity Income was $28.1 million in Q2 2022, compared to $25.1 million in Q1 2022 and $35.3 million in Q4 2021.